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STAT5 programs a distinct subset of GM-CSF-producing 
T helper cells that is essential for autoimmune 
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T helper (TH)-cell subsets, such as TH1 and TH17, mediate inflammation in both peripheral tissues and central ner-
vous system. Here we show that STAT5 is required for T helper-cell pathogenicity in autoimmune neuroinflammation 
but not in experimental colitis. Although STAT5 promotes regulatory T cell generation and immune suppression, loss 
of STAT5 in CD4+ T cells resulted in diminished development of experimental autoimmune encephalomyelitis (EAE), 
a mouse model of multiple sclerosis. Our results showed that loss of encephalitogenic activity of STAT5-deficient au-
toreactive CD4+ T cells was independent of IFN-γ or interleukin 17 (IL-17) production, but was due to the impaired 
expression of granulocyte-macrophage colony-stimulating factor (GM-CSF), a crucial mediator of T-cell pathoge-
nicity. We further showed that IL-7-activated STAT5 promotes the generation of GM-CSF-producing CD4+ T cells, 
which were preferentially able to induce more severe EAE than TH17 or TH1 cells. Consistent with GM-CSF-produc-
ing cells being a distinct subset of TH cells, the differentiation program of these cells was distinct from that of TH17 
or TH1 cells. We further found that IL-3 was secreted in a similar pattern as GM-CSF in this subset of TH cells. In 
conclusion, the IL-7-STAT5 axis promotes the generation of GM-CSF/IL-3-producing TH cells. These cells display a 
distinct transcriptional profile and may represent a novel subset of T helper cells which we designate as TH-GM.
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Introduction
In response to antigenic assault, naïve CD4+ T cells 
differentiate into various subsets of effector T helper (TH) 
cells with differential cytokine production profiles and 
distinct functions [1-3]. Inflammatory cytokines direct 
the differentiation of antigen-specific CD4+ T cells by 
inducing the expression of subset-specific transcription 
factors [1]. For instance, interleukin 12 (IL-12) activates 
STAT4 and induces T-bet expression, which promotes 
TH1 differentiation and IFN-γ production [4-6]. IL-6 
signaling through STAT3, in concert with TGF-β, induc-
es RORγt expression and initiates the differentiation of 
TH17 cells [7-9], which is further enhanced by TNF-α, 
IL-23, and IL-1β [10].
By coordinating both innate and adaptive effector cell 
activities, CD4+ T cells including TH1, TH2, and TH17 
play critical roles in host defense against infectious 
agents and in the pathogenesis of various autoimmune 
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diseases [11]. For example, both TH1 and TH17 cells are 
considered major mediators of autoimmune neuroinflam-
mation in multiple sclerosis (MS) and experimental auto-
immune encephalomyelitis (EAE) [2, 12, 13]. However, 
mice deficient in IFN-γ or IL-12 (p35) show exacerbated 
EAE development, whereas mice deficient in IL-23 (p19) 
are resistant to EAE [14-17]. Loss of RORγt or STAT3, 
the master regulators of TH17 cells, attenuates the devel-
opment of EAE [8, 18]. These studies suggest that TH17, 
rather than TH1 cells, are the main encephalitogenic pop-
ulation in autoimmune neuroinflammation. However, the 
role of TH17 in MS and EAE is still in debate since none 
of the TH17-hallmark cytokines, including IL-17, IL-
17F, and IL-22, is mandatory for EAE development [12, 
19, 20]. More recently, granulocyte-macrophage colo-
ny-stimulating factor (GM-CSF) secreted by autoreactive 
T cells was identified as a potential encephalitogenic fac-
tor to sustain neuroinflammation [21-23]. 
STAT5 transmits IL-2 signal and is crucial for regu-
latory T (Treg) cell development [24], but also negatively 
regulates TH17 differentiation [25, 26]. However, its 
function in T cell-mediated autoimmune diseases has not 
been well documented. In this study, surprisingly, we 
found that STAT5 was indispensible for the encephali-
togenicity of autoreactive CD4+ T cells in EAE. Further 
investigation showed that IL-7-STAT5 signaling axis 
induced optimal GM-CSF production in pathogenic 
CD4+ T cells, which was important for inducing effec-
tive neuroinflammation. In vitro studies showed that 
GM-CSF-producing CD4+ T cells regulated by IL-7-
STAT5 signaling axis may represent a new TH subset 
with a distinct differentiation program and cytokine pro-
duction profile. 
Results
Mice with Stat5 deletion in T cells are resistant to EAE
To examine the role of STAT5 in T cell-mediated 
pathogenesis, we induced EAE in Cd4-Cre; Stat5f/f 
(Stat5−/−) mice [27], where Stat5a/b loci were specifically 
deleted in CD4+ and CD8+ T cells, and Stat5f/f (Stat5+/+) 
mice. We found diminished incidence and severity of 
EAE disease in Stat5−/− mice compared with Stat5+/+ 
mice (Figure 1A and Supplementary information, Figure 
S1A and S1B), which was opposite to our expectation 
based on an inhibitory role of STAT5 in TH17 generation. 
Consistent with EAE resistance, we found a remarkable 
reduction of immune cell infiltration in the CNS of Stat5/− 
mice (Figure 1B and Supplementary information, Fig-
ure S1C-S1F). However, the frequencies of IL-17+ and 
IFN-γ+ cells among CD4+ T cells in the central nervous 
system (CNS) were comparable between Stat5+/+ and 
Stat5−/− mice (Figure 1C), suggesting that the resistance 
to EAE in Stat5−/− mice is independent of TH1 and TH17 
cells. Furthermore, we detected decreased CD4+CD25+ 
population and reduced Foxp3 expression in Stat5−/− 
mice (Figure 1D and Supplementary information, Figure 
S2A), indicating the resistance to EAE is unlikely due to 
altered Treg cell development.
Intrinsic defect in encephalitogenicity of STAT5-deficient 
CD4+ T cells
To examine whether T cell-specific deletion of Stat5 
resulted in peripheral lymphopenia, we analyzed T cell 
populations in spleens of MOG35-55/CFA-immunized 
mice. Consistent with a previous report [28], we detect-
ed reduced CD8+ T cell number but similar number of 
CD4+ T cells in Stat5−/− mice compared with Stat5+/+ 
mice (Supplementary information, Figure S2B and S2C). 
Furthermore, we detected increased frequencies of both 
IL-17+ and IFN-γ+ CD4+ T cells in the spleens of Stat5−/− 
mice (Supplementary information, Figure S2D). To val-
idate the function of STAT5 in TH1 and TH17 generation, 
we performed in vitro T-cell differentiation. As reported 
[25, 26], STAT5 mediated the suppressive effect of IL-2 
on TH17 differentiation (Supplementary information, 
Figure S3A and S3B). STAT5 deficiency led to slightly 
decreased TH1-cell generation (Supplementary informa-
tion, Figure S3C). Therefore, the resistance to EAE in 
Stat5−/− mice is unlikely due to impaired TH1- and TH17-
cell generation in vivo.
To address whether the resistance to EAE in Stat5−/− 
mice is caused by STAT5 deficiency in CD4+ T cells, 
we reconstituted Rag2−/− mice with Stat5+/+ or Stat5−/− 
CD4+ T cells followed by EAE induction. We found 
that Rag2−/− mice receiving Stat5−/− CD4+ T cells were 
resistant to the disease compared with mice receiving 
Stat5+/+ CD4+ T cells (Supplementary information, Fig-
ure S4A and S4B), demonstrating that Stat5−/− CD4+ T 
cells were impaired in mediating EAE development. The 
expression of chemokine receptors such as CCR6 and 
CXCR3, which are critical for TH17 or TH1 cell entry into 
the CNS [29, 30], was not impaired in Stat5−/− CD4+ T 
cells (Supplementary information, Figure S5A), indicat-
ing that CD4+ T cells with STAT5 deficiency are likely 
capable of infiltrating the CNS. Consistent with this, we 
observed comparable numbers of CD4+ T cells in the 
CNS of Stat5+/+ and Stat5−/− mice before disease onset 
(on days 7 and 9) (Supplementary information, Figure 
S5B). However, during the later phase, significantly 
more CD4+ T cells accumulated in the CNS of Stat5+/+ 
mice compared with Stat5−/− mice (Supplementary infor-
mation, Figure S5C). These results indicate that Stat5−/− 
CD4+ T cells can infiltrate the CNS but fail to induce 
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Figure 1 Stat5-conditional knockout mice are resistant to EAE. (A) Clinical EAE scores (left) and incidence (right, n = eigh-
teen of three experiments pooled) of Stat5+/+ and Stat5−/− mice immunized twice with MOG35-55/CFA. (B) Histology of spi-
nal cord sections obtained from EAE mice on day 9 after 2nd immunization. Scale bars, 200 µm (top), 50 µm (bottom). (C) 
Flow cytometric analysis of IL-17 and IFN-γ expression by CNS-infiltrating CD4+ T cells at peak of disease. (D) Percentage 
of CD4+CD25+ T cells in the CNS at peak of disease (n = 3). (E, F) Clinical EAE scores (E, left) and incidence (E, right) of 
Rag2−/− mice (n = 5 per group) after adoptive transfer of 2 × 106 MOG35-55-reactive Stat5
+/+ or Stat5−/− CD4+ T cells, respective-
ly. IL-17 and IFN-γ expression by CNS-infiltrating CD4+ T cells was measured by intracellular cytokine staining at the peak of 
disease (F). Data represent at least two independent experiments. *P < 0.05; ns, not significant.
effective inflammatory responses. To further exclude 
the possibility that EAE resistance is due to reduction in 
Stat5−/− CD4+ T cell number in the CNS, we transferred 
more Stat5−/− CD4+ T cells than Stat5+/+ cells into Rag2−/− 
mice followed by MOG35-55/CFA immunization, so that 
comparable numbers of autoreactive CD4+ T cells were 
present in the CNS after disease onset. We still observed 
reduced disease severity in mice receiving Stat5−/− CD4+ 
T cells (Supplementary information, Figure S6A and 
S6B). Together, these results suggest that the resistance 
to EAE disease caused by STAT5 deficiency in CD4+ T 
cells is unlikely due to impaired CD4+ T cell infiltration 
or survival in the CNS.
To confirm that EAE resistance caused by STAT5 
deficiency is due to intrinsic impairment of autoreactive 
CD4+ T cells, we isolated CD4+ T cells from MOG35-55/
CFA-immunized mice and transferred ex vivo-expanded 
MOG35-55-reactive Stat5
+/+ and Stat5−/− CD4+ T cells into 
Rag2−/− mice separately without additional immuniza-
tion. Mice receiving Stat5+/+ cells developed EAE 1 week 
after the transfer (Figure 1E). In contrast, mice receiving 
Stat5−/− CD4+ T cells had significantly reduced disease 
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severity and incidence (Figure 1E). Of note, the frequen-
cies of IL-17+ and/or IFN-γ+ cells among CD4+ T cells in 
the CNS were comparable between the two groups (Fig-
ure 1F). CD4+ and CD8+ T cell co-transfer experiments 
demonstrate that the resistance to EAE observed in 
Stat5−/− mice was not due to CD8+ T cells (Supplementary 
information, Figure S7A and S7B). Therefore, Stat5−/− 
CD4+ T cells are intrinsically defective in encephalitoge-
nicity, independent of TH1- and TH17-cell generation.
STAT5 deficiency in CD4+ T cells causes impaired ex-
pression of GM-CSF
Communication between CNS-infiltrating CD4+ T 
cells and myeloid cells is critical for inducing effective 
neuroinflammation [21, 22]. GM-CSF production by 
encephalitogenic CD4+ T cells, not other types of cells, 
is essential for microglial cell activation, peripheral my-
eloid cell recruitment and EAE development [23]. To 
test whether GM-CSF production was impaired upon 
Stat5 depletion, we examined GM-CSF expression in 
MOG35-55-specific CD4
+ T cells. We found that GM-CSF 
production was robustly increased in a dose-dependent 
manner in Stat5+/+, but not in Stat5−/− cells, upon antigen 
re-stimulation (Figure 2A). Antigen-specific CD4+ T cells 
with STAT5 deficiency contained significantly reduced 
percentages of GM-CSF-producers in both IL-17+ and 
IL-17− populations (Figure 2B). Of note, the frequency 
of IL-17-producing CD4+ T cells was increased with 
STAT5 deficiency (Figure 2B). Together, these results 
suggest that STAT5 is required for GM-CSF expression 
by antigen-specific CD4+ T cells.
Next, we examined GM-CSF expression in the CNS 
during EAE development. Although IL-17 and IFN-γ 
expression by CNS-infiltrating Stat5−/− CD4+ T cells was 
not impaired (Figure 1C), we detected a significantly di-
minished frequency of CD4+GM-CSF+ cells in the CNS 
of Stat5−/− mice compared with control mice (Figure 2C). 
Similarly, in passive EAE induction, Rag2−/− mice trans-
ferred with STAT5-deficient MOG35-55-reactive CD4
+ 
T cells also showed a reduced frequency of CD4+GM-
CSF+ T cells in the CNS compared with mice transferred 
with wild-type (WT) cells (Figure 2D). Time-course 
analysis of cytokine induction in the whole CNS tissues 
showed that GM-CSF mRNA expression in Stat5+/+ mice 
was markedly increased as early as day 8 after MOG35-
55/CFA immunization, whereas GM-CSF induction in 
Stat5−/− mice was significantly diminished (Figure 2E). 
Meanwhile, no significant difference in IL-17 or IFN-γ 
expression was detected between Stat5−/− and Stat5+/+ 
mice on day 8 post-immunization (Figure 2E). The re-
duced IL-17 expression in the CNS of Stat5−/− mice at 
a later stage (day 14, Figure 2E) could be explained by 
the inability of Stat5−/− CD4+ T cells to induce effective 
neuroinflammation with a result of decreased inflamma-
tory cell infiltration (Supplementary information, Figures 
S1 and S5C). We also observed the expression level 
of IL-23, an important inflammatory cytokine mainly 
produced by dendritic cells (DCs) [16], was reduced in 
the CNS of Stat5−/− mice compared with Stat5+/+ mice, 
paralleling decreased IL-17 expression level (Figure 2E). 
Interestingly, the expression level of IL-23 in the CNS of 
Stat5+/+ mice was only significantly increased on day 14 
after disease induction (Figure 2E), suggesting that IL-
23 might not be required for GM-CSF expression and 
EAE induction at the early stage. Together, these results 
demonstrate that STAT5 deficiency in CD4+ T cells re-
sults in impaired GM-CSF expression, which is associat-
ed with EAE resistance.
IL-7-STAT5 signaling induces GM-CSF expression in au-
toreactive CD4+ T cells
We next investigated the possible cytokine(s) that 
signal through STAT5 to regulate GM-CSF expression. 
We stimulated CD4+ T cells with IL-23 and IL-1β, two 
cytokines that drive GM-CSF expression in TH17 cells 
[21, 22]. We found that neither IL-23 nor IL-1β was able 
to induce STAT5 activation (Figure 3A). Furthermore, 
IL-1R1 expression was not changed, whereas IL-23Rα 
expression was increased in Stat5−/− CD4+ T cells (Figure 
3B), indicating that STAT5-mediated GM-CSF expres-
sion is unlikely dependent on IL-23 and IL-1β signaling. 
In contrast, both IL-2 and IL-7 potently activated STAT5 
(Figure 3A). Therefore, we further examined the roles 
of these two cytokines in GM-CSF induction in CD4+ T 
cells. Splenocytes were isolated from MOG35-55/CFA-im-
munized mice before disease onset and challenged with 
MOG35-55 alone versus in the presence of IL-2 or IL-7 ex 
vivo. We did not detect an obvious effect of IL-2 on the 
frequency of GM-CSF-producing cells in CD4+CD44hi 
population (Supplementary information, Figure S8). In 
contrast, IL-7 significantly increased the frequency of 
GM-CSF-producing cells in CD4+CD44hi population and 
GM-CSF secretion in a STAT5-dependent manner (Figure 
3C and 3D).
IL-7Rα is expressed by naïve and effector CD4+ T 
cells, suggesting that IL-7 may directly act on both pop-
ulations to regulate GM-CSF expression. To address 
this, sorted CD62LhiCD44lo (naïve) and CD62LloCD44hi 
(effector) CD4+ T cells from Stat5−/− and Stat5+/+ mice 
during EAE development were activated by anti-CD3 
plus anti-CD28 in the presence or absence of IL-7, 
followed by GM-CSF expression examination. As shown 
in Figure 3E, CD62LloCD44hi T cells expressed GM-CSF 
more robustly than CD62LhiCD44lo cells. IL-7 promoted 
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Figure 2 Diminished induction of GM-CSF in Stat5−/− CD4+ T cells. (A, B) Splenocytes were obtained from MOG35-55/CFA-im-
munized Stat5+/+ and Stat5−/− mice (n = 3 per group) before disease onset and challenged with MOG35-55 at various concen-
trations for 24 h. GM-CSF secretion was measured by ELISA (A). Golgiplug was added in the last 4 h of MOG35-55 (20 µg/ml) 
challenge and the frequencies of IL-17+ and GM-CSF+ cells among CD4+CD44hi T cells were measured (B). (C) IL-17, IFN-γ 
and GM-CSF expression by CNS-infiltrating CD4+ T cells of Stat5+/+ and Stat5−/− mice was measured by intracellular cytokine 
staining at peak of disease. (D) IL-17, IFN-γ, and GM-CSF expression by CNS-infiltrating CD4+ T cells of Rag2−/− recipient 
mice at peak of EAE induced by adoptive transfer of MOG35-55-reactive CD4
+ T cells. (E) CNS tissues were collected from 
naïve or MOG35-55/CFA-immunized mice for RNA extraction (n = 3 per group at each time point). Time-course analysis of cyto-
kine mRNA expression was performed with RT-PCR. The RT-PCR data were normalized to Rn18S, and expression in naïve 
mice was set to 1. Data represent two independent experiments. *P < 0.05.
GM-CSF expression in both cell subsets, which was ab-
rogated by STAT5 deficiency (Figure 3E). 
Consistent with the facilitating effect of IL-7-depen-
dent T-cell differentiation on EAE, mice treated with an 
IL-7Rα-specific antibody (clone SB/14) during EAE de-
velopment showed a significant reduction of disease se-
verity accompanied with reduced CNS inflammation, but 
without T cell depletion [31] (Supplementary informa-
tion, Figure S9A-S9C). Notably, blocking IL-7 signaling 
resulted in decreased GM-CSF expression in CNS-infil-
trating CD4+ T cells (Supplementary information, Figure 
S9D-S9F). These findings demonstrate that IL-7 induces 
STAT5 activation to promote GM-CSF expression in 
autoreactive CD4+ T cells, which is critical for the devel-
opment of neuroinflammation.
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Figure 3 IL-7 promotes GM-CSF expression through STAT5 activation in autoreactive CD4+ T cells. (A) Purified CD4+ T cells 
were cultured with TGF-β and IL-6 for 3 days, followed by resting for 6 h. Then cells were treated with various cytokines for 30 
min, and pSTAT3 and pSTAT5 levels were determined by immunoblotting. STAT3 and STAT5 were further detected after strip-
ping. (B) The mRNA expression of IL-23Rα and IL-1R1 in splenic CD4+ T cells of Stat5+/+ and Stat5−/− EAE mice (n = 3). (C, D) 
Splenocytes were obtained from MOG35-55/CFA-immunized Stat5
+/+ and Stat5−/− mice before disease onset and challenged with 
MOG35-55 (20µg/ml) in the absence or presence of IL-7 for 48 h. Frequencies of GM-CSF
+ and IL-17+ cells among CD4+CD44hi 
T cells were measured by intracellular cytokine staining and flow cytometry (C). Right panel in C shows overall frequencies of 
GM-CSF+ and IL-17+ cells in Stat5+/+ group (n = 3). GM-CSF secretion was measured by ELISA (D). Data represent two inde-
pendent experiments with three mice per group. (E) Splenic CD62LhiCD44lo and CD62LloCD44hi T cells from MOG35-55/CFA-im-
munized mice were sorted out. Cells were stimulated with anti-CD3 and anti-CD28 in the absence or presence of IL-7 for 4 h 
and then harvested for the analysis of GM-CSF expression by RT-PCR. *P < 0.05; ns, not significant.
TH17 or TH1 differentiation condition inhibits GM-CSF 
expression
To further understand IL-7/STAT5-mediated GM-CSF 
expression in CD4+ T cells, we stimulated naïve CD4+ 
T cells with various conditions. We found that anti-CD3 
together with anti-CD28 induced the expression of both 
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GM-CSF and IFN-γ (Supplementary information, Fig-
ure S10A). Interestingly, both TH1 (IL-12 + anti-IL-4) 
and TH17 (blocking both IFN-γ and IL-4 in combination 
with TGF-β + IL-6 or IL-6 + IL-23 + IL-1β) differen-
tiation conditions greatly suppressed the expression of 
GM-CSF (Figure 4A and 4B). Conversely, neutraliza-
tion of both IL-12 and IFN-γ promoted the generation 
of GM-CSF-producing cells, consistent with a previous 
report [21], which was not affected by IL-23 and IL-1β 
(Figure 4A). In addition to TGF-β-mediated inhibition of 
GM-CSF expression [22], we found that IL-6, an essen-
tial cytokine for TH17 differentiation, had a profound in-
hibitory effect on GM-CSF expression (Figure 4C), indi-
cating that STAT3 could be a negative regulator of GM-
CSF expression. We used STAT3-deficient CD4+ T cells 
to test this hypothesis. As expected, naïve Stat3−/− CD4+ 
T cells were impaired in TH17 differentiation (Supple-
mentary information, Figure S10B). In WT cells, TH17 
differentiation condition (anti-IFN-γ + anti-IL-4 + IL-6 
+ IL-23 + IL-1β) greatly inhibited GM-CSF expression 
(Figure 4A). However, deficiency of STAT3 abrogated 
the inhibitory effect of IL-6 on GM-CSF expression 
(Supplementary information, Figure S10B). Interest-
ingly, even without exogenous IL-6, STAT3 exhibited 
a suppressive effect on GM-CSF expression as Stat3−/− 
cells showed increased GM-CSF expression compared 
to WT cells (Supplementary information, Figure S10B). 
In addition, GM-CSF expression in CD4+ T cells is inde-
pendent of RORγt and T-bet [22]. Thus, our data support 
that differentiation of GM-CSF-producing CD4+ T-cell is 
distinct from TH1 or TH17.
IL-7-STAT5 promotes GM-CSF-producing TH-cell differ-
entiation
Our findings above suggest the possibility of a poten-
tial new TH cell subset that is regulated by IL-7-STAT5 
signaling. To further test this possibility, we investigated 
GM-CSF-producing TH cell differentiation in vitro by 
activating naïve CD4+ T cells with anti-CD3 and an-
ti-CD28 in the presence of different concentrations of 
IL-7. We found that addition of 0.5 ng/ml IL-7 greatly 
increased the frequency of GM-CSF-producing cells and 
the secretion of GM-CSF, which were further increased 
upon increase in IL-7 concentration (1 ng/ml) (Figure 4D 
and 4E). Without STAT5, IL-7 was unable to promote the 
generation of GM-CSF-producing cells (Figure 4F and 
4G). Chromatin immunoprecipitation (ChIP) analysis 
showed that IL-7 activated STAT5 directly bound to pro-
moter regions of the Csf2 gene (Supplementary informa-
tion, Figure S11A and S11B). We noticed the presence of 
a small proportion of IFN-γ-producing cells in this con-
dition (Figure 4D). Therefore, we included IFN-γ-block-
ing antibody in the culture and found that a combination 
of IL-7 and anti-IFN-γ induced the highest frequency of 
GM-CSF+ cells, where few IL-17+ or IFN-γ+ cells were 
detected (Figure 4H). Therefore, the in vitro generation 
of GM-CSF-producing TH cells requires the transcription 
factor STAT5, optimal concentration of IL-7, and IFN-γ 
neutralization in addition to TCR and CD28 signaling.
GM-CSF-producing TH cells represent a potential new 
subset distinct from TH1 or TH17
To further characterize GM-CSF-producing TH cells, 
we differentiated TH1, TH17, and GM-CSF-producing TH 
cells from naïve CD4+ T cells in vitro. The expression of 
RORγt and T-bet was examined. We found that unlike 
TH1 or TH17 cells, the expression of T-bet or RORγt was 
minimal in GM-CSF-producing TH cells (Figure 5A). 
Next, we performed microarray analysis to examine gene 
expression profiles of TH1, TH17, and GM-CSF-produc-
ing TH cells. We identified a list of 202 genes preferen-
tially expressed in TH1 cells compared with naïve, TH17 
and GM-CSF-producing TH cells, among which IFN-γ, 
Gzmb, and T-bet were on the top of the list (Figure 5B, 
left panel and Supplementary information, Table S1). 
Similarly, TH17 feature genes, including IL-17, IL-
17F, RORγt, and RORα, were identified in the list of 
411 genes specific to TH17 cells (Figure 5B, middle 
panel, and Supplementary information, Table S1). The 
GM-CSF-producing TH cell-specific gene list contains 
210 genes with genes encoding GM-CSF and IL-3 as the 
top genes in the list (Figure 5B, right panel and Supple-
mentary information, Table S1).
Next, we further verified the microarray findings. 
Cytokine expression analysis showed that GM-CSF was 
predominately expressed in GM-CSF-producing TH cells 
compared with TH1 or TH17 cells (Figure 5C and 5D). In-
terestingly, IL-3, a cytokine that is coregulated with GM-
CSF [32], was also highly expressed in GM-CSF-pro-
ducing TH cells, not TH1 or TH17 cells (Figure 5D). Fur-
ther examination showed that IL-3 expression was also 
regulated by IL-7-STAT5 signaling (Figure 5E and 5F).
IL-2, which also signals through STAT5, did not 
promote GM-CSF-producing TH differentiation (Supple-
mentary information, Figure S12A), possibly due to the 
lack of IL-2Rα expression on naïve CD4+ T cells and 
thus the unresponsiveness of STAT5 to the IL-2 signal 
early in differentiation (Supplementary information, 
Figure S12B-S12D). To further confirm this possibility, 
we stimulated activated CD4+ T cells with IL-2 or IL-
7, and found both cytokines induced STAT5 activation, 
STAT5 binding to Csf2 promoter, and increase in GM-
CSF mRNA levels (Supplementary information, Figure 
S13A-S13C). Notably, IL-2 induced a prolonged STAT5 
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Figure 4 Regulation of GM-CSF-producing TH cells in vitro. (A-E) Naïve CD4+ T cells were primed with plate-bound anti-CD3 
and soluble anti-CD28 in the presence of a combination of various cytokines and neutralizing antibodies as indicated. GM-
CSF, IL-17, and IFN-γ expression was analyzed by intracellular cytokine staining (A, C, D), RT-PCR (B) or ELISA (E). (F, G) 
Stat5+/+ and Stat5−/− naïve CD4+ T cells were activated with anti-CD3 and anti-CD28 in the presence IL-7 for 3 days. GM-CSF, 
IL-17, and IFN-γ expression was analyzed by intracellular cytokine staining (F). GM-CSF secretion was measured by ELISA 
(G). (H) Naïve CD4+ T cells were activated with anti-CD3 and anti-CD28 in the presence of IL-7 or/and anti-IFN-γ as indicat-
ed. GM-CSF, IL-17, and IFN-γ expression was analyzed. Data represent more than two independent experiments. *P < 0.05; 
ns, not significant.
Wanqiang Sheng et al.
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activation compared with IL-7 (Supplementary informa-
tion, Figure S13A).
To test the hypothesis that the GM-CSF-producing 
TH subset is the primary encephalitogenic effector cells, 
we performed adoptive transfer of different subsets of 
MOG35-55-reactive CD4
+ T cells into Rag2−/− mice for 
EAE induction. As shown in Figure 5G, GM-CSF-pro-
ducing TH cells were preferentially able to induce a more 
robust EAE compared with TH17 and TH1 subsets.
Together, these data demonstrate that IL-7-STAT5-
signaling controls the differentiation of a new T helper 
cell subset that is distinct from TH1 or TH17 and predom-
inantly expresses GM-CSF and IL-3.
STAT5-deficient CD4+ T cells retain the capacity to in-
duce colitis
The finding from the EAE model prompted us to test 
whether STAT5-deficient T cells also lacked pathogenic-
ity in other T cell-mediated autoimmune diseases. We as-
sessed the pathogenic potential of STAT5-deficient auto-
reactive CD4+ T cells in colitis by reconstituting Rag2−/− 
mice with Stat3−/−, Stat5−/− or WT CD4+CD25−CD45RBhi 
naïve T cells. Consistent with a previous report [33], 
mice reconstituted with Stat3−/− T cells continued to gain 
weight, whereas mice receiving Stat5−/− or WT T cells 
lost weight (Figure 6A), and showed enlarged spleens 
and mesenteric lymph nodes (MLNs) (Figure 6B). 
Marked colonic inflammation and inflammatory cell in-
filtration in the colon were observed in mice that received 
either WT or Stat5−/− T cells at 8 weeks after reconstitu-
tion (Figure 6C and 6D). Consistent with the resistance 
to colitis in mice receiving Stat3−/− cells, an obviously 
reduced frequency of CD4+ T cells and IL-17-producing 
CD4+ T cells in their lamina propria lymphocytes (LPLs) 
was observed compared with mice receiving Stat5−/− 
or WT cells (Figure 6D and 6E). There was no defect 
in either IL-17 or IFN-γ production by CD4+ T cells in 
LPLs of mice reconstituted with Stat5−/− T cells (Fig-
ure 6E). However, we detected a significant reduction 
in GM-CSF-producing T cells in the absence of STAT5 
when transferred into Rag2−/− mice (Figure 6E). There-
Figure 5 Distinct features of GM-CSF-producing TH cells. (A) The mRNA expression of T-bet and RORγt in naïve, TH1 (IL-
12 + anti-IL-4), TH17 (TGF-β + IL-6 + anti-IFN-γ + anti-IL-4) and GM-CSF-producing TH (IL-7 + anti-IFN-γ) cells. The RT-PCR 
data were normalized to Gapdh, and expression in naïve T cells was set to 1. (B) Naïve CD4+ T cells were differentiated into 
TH1, TH17 and GM-CSF-producing (GM-CSF
+) TH cells in vitro. Microarray analysis was performed to examine their gene ex-
pression profiles. Hierarchical clusters of preferentially expressed genes for TH1, TH17, or GM-CSF-producing TH cells were 
shown (biological duplication). (C) GM-CSF secretion by three TH subsets in vitro. (D) Flow cytometric analysis of cytokine 
expression (GM-CSF, IL-3, IL-17, and IFN-γ) by three TH subsets in vitro. (E) Frequency of IL-3+ cells generated with or with-
out IL-7. (F) GM-CSF and IL-3 expression by WT or STAT5-deficient GM-CSF-producing TH cells. (G) Clinical EAE scores of 
Rag2−/− mice (n = 3-6 mice per group) after adoptive transfer of 6 × 105 various MOG35-55-reactive TH subsets. Data represent 
two independent experiments. *P < 0.05.
fore, GM-CSF-producing CD4+ T cells might not play a 
critical role in colitis. This view was further supported 
by the observation that although there were comparable 
GM-CSF+ cells in Stat3−/− and WT-transferred T cells, 
Stat3−/− CD4+ T cells failed to induce colitis.
Discussion
Effector TH cells, differentiated from naïve T cells after 
TCR-mediated antigen recognition with the influence of 
costimulation and the instruction from specific cytokines, 
are classified by their specific cytokine expression and 
immune-modulatory functions [1, 3, 34]. Here we have 
demonstrated that IL-7, signaling through STAT5, in-
duces the development of a potential new TH subset that 
predominantly expresses GM-CSF (GM-CSF-producing 
TH cells). In addition to GM-CSF, we identified that this 
TH subset highly expresses IL-3, a cytokine important in 
regulating the function of myeloid-derived immune cells. 
The development of GM-CSF-producing TH cells is in-
dependent of the mechanisms required for TH1 or TH17 
development. In fact, conditions for TH1 or TH17 differ-
entiation suppressed the development of GM-CSF-pro-
ducing TH cells. It is known that differentiated effector 
TH cells could produce specific cytokines to create a cy-
tokine environment that favors the differentiation of their 
own while suppressing the differentiation of other TH 
subsets. For instance, IL-12 as well as IFN-γ induces TH1 
differentiation. The differentiated TH1 cells produce large 
amounts of IFN-γ to amplify TH1 differentiation, whereas 
they suppress TH17 or GM-CSF-producing TH differenti-
ation. It is possible that the GM-CSF-producing TH cells 
produce certain cytokines to promote the differentiation 
of their own, but suppress the differentiation of TH1 and/
or TH17 cells. It is also possible that this new subset of 
TH cells produce cytokines such as GM-CSF to enhance 
TH1 or TH17 responses via inducing the production of in-
flammatory cytokines from myeloid cells. Further studies 
are needed to explore such possibilities.
While this manuscript was under submission, a report 
was published, showing that IL-17 and GM-CSF expres-
Wanqiang Sheng et al.
1397
npg
www.cell-research.com | Cell Research
Figure 6 STAT5 is not required in T cell-dependent colitis. (A) Rag2−/− mice were reconstituted with CD4+CD25−CD45RBhi 
naïve T cells derived from WT, Stat3−/− or Stat5−/− mice (3-5 mice per group). Body weight loss was monitored and calculated 
over 7 weeks. Data are representative of two independent experiments. (B) Systemic inflammation was assessed by compar-
ing size of spleen and MLNs 8 weeks after transfer. (C) Colonic inflammation was assessed histologically. Images shown are 
representative of three mice per group. (D) Percentages of CD4+ T cells and CD11b+ cells in MLNs and LPLs were analyzed 
by flow cytometry. Data are representative of at least three mice per group. (E) IL-17, IFN-γ, and GM-CSF production by 
CD4+ T cells in LPLs was measured. *P < 0.05, **P < 0.005.
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sion in human TH cells are antagonistically regulated [35]. 
Similar to our finding in mice, Noster et al. [35] found 
that GM-CSF-producing TH cells represent a substantial 
population in the cerebrospinal fluid of MS patients, 
suggesting a pathogenic role of these cells in neuroin-
flammation. Our work utilizing the mouse model for a 
thorough functional study has provided clear genetic ev-
idence showing the essential role of STAT5 in GM-CSF 
and IL-3 production in this novel TH cell subset. This 
subset is essential, even in the context of normal TH1 or 
TH17 activity, for the pathogenesis of EAE. We propose 
to tentatively refer to this T helper cell subset as TH-GM, 
which is critically regulated by STAT5 and predominant-
ly produces GM-CSF and IL-3. 
GM-CSF governs the activities of myeloid-derived 
cell populations and is implicated in various inflammato-
ry and autoimmune diseases such as rheumatoid arthritis 
(RA) and MS. Therapeutic interventions targeting GM-
CSF, such as Mavrilimumab (human anti-GM-CSFRα 
Ab) and MOR103 (human anti-GM-CSF mAb), are un-
der phase 2 clinical trial in RA and RA/MS, respectively 
(clinicaltrials.gov). IL-3 is a cytokine also involved in 
several autoimmune diseases [36-39]. Therefore, directly 
targeting this new subset of TH cells, the dominant source 
of such pathogenic mediators, in various autoimmune 
diseases could lead to better outcomes than targeting a 
single factor, such as GM-CSF or IL-3. 
STAT5 transmits IL-2 signals. A previous widely ac-
cepted model is that T-cell survival and proliferation re-
quire IL-2, based on studies using in vitro systems. There 
is now much evidence arguing that IL-2 is dispensable 
for the induction of T cell-dependent immunity in vivo 
[40]. In our EAE model, we indeed observed Stat5-con-
ditional knockout mice had fewer CD4+ T cells in the 
CNS after disease onset as STAT5-deficient CD4+ T cells 
had inability to induce effective inflammatory respons-
es. However, in EAE induced by CD4+ T cell transfer, 
STAT5-deficient CD4+ T cells with a number comparable 
to that of WT cells in the CNS still failed to induce the 
disease (Supplementary information, Figure S6A and 
S6B). These results suggest that the role of STAT5 in 
CD4+ T cell survival and proliferation is unlikely the ma-
jor causal factor of EAE resistance in Stat5-conditional 
knockout mice. 
IL-7, signaling through the common γc and IL-7Rα, 
is required for T cell homeostasis [41]. A previous re-
port showed that IL-7 could acutely stimulate GM-CSF 
production from memory T cells [42]. Here, our work 
demonstrates that IL-7 through STAT5 activation induc-
es the generation of pathogenic TH-GM cells for GM-
CSF production in mediating neuroinflammation. Our 
finding is in line with the association of IL-7Rα variants 
with MS in patient GWAS and the beneficial effect of 
IL-7Rα-neutralizing antibody in EAE treatment [43-45]. 
A recent report indicates IL-7 promotes IFN-γ production 
by TH1 cells and contributes to a TH1-driven subtype of 
MS [45]. However, mice deficient in IFN-γ show exacer-
bated EAE development [15]. Thus, the requirement for 
IL-7 in EAE development is unlikely due to its role in 
promoting IFN-γ production.
The function of IL-23, a cytokine required for TH17 
terminal differentiation [46], in EAE suggests the in-
volvement of TH17 cells in this disease [16]. However, 
the major cytokines produced by TH17 cells, IL-17A, IL-
17F, and IL-22, were found to be dispensable for the de-
velopment of EAE [19, 20]. However, IL-23 was found 
to induce the expression of GM-CSF in TH17 cells, a fac-
tor essential for encephalitogenicity of T cells [21, 22], 
which seems to strengthen the link between TH17 cells 
and EAE. Paradoxically, a recent study reported IL-23/
RORγt axis-suppressed GM-CSF expression in human 
TH cells [35]. Moreover, anti-IL-23 receptor antibodies 
that worked well for treating peripheral inflammation 
such as psoriasis failed in treating MS [47], suggesting 
that the function of IL-23 in MS could be compensated 
by other factors. In this study, we found that TH-GM cells 
produced greater amounts of GM-CSF than TH1 or TH17 
cells (Figure 5), suggesting that TH-GM cells are the 
major source of GM-CSF in T cell-mediated neuronal 
inflammation. Interestingly, we found that the expres-
sion of IL-23p19 in CNS during EAE development only 
occurred after the onset of the disease and Stat5 gene 
deletion in T cells abolished its expression (Figure 2E), 
suggesting that IL-23 is not required for the initiation of 
EAE and signaling transduced by STAT5 is required for 
IL-23 expression in CNS in neuronal inflammation. It is 
possible that GM-CSF-producing TH-GM cells provide 
GM-CSF to induce the expression of IL-23 from DCs, 
macrophages, and other CNS-residential cells to sustain 
the inflammation. Therefore, our study does not exclude 
a scenario where GM-CSF-producing TH-GM cells coop-
erate with TH1 and/or TH17 to mediate the development 
of EAE. Further study on TH-GM cells including their 
physiological functions is warranted for targeting these 
cells for the development of therapeutic interventions for 
human inflammatory diseases such as MS.
It is interesting to see that STAT5-regulated TH-GM 
cells are not required in a T-cell transfer model of colitis 
(Figure 6). EAE represents sterile CNS inflammation, in 
which autoreactive CD4+ T cells are the major producers 
of GM-CSF, a factor crucial for EAE pathogenesis [23]. 
However, numerous inflammatory cytokines, such as 
TH1-related IFN-γ and TH17-related IL-17F, are impli-
cated in the pathogenesis of colitis [48]. STAT5-deficient 
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CD4+ T cells are not impaired in TH1 or TH17 generation. 
In addition, GM-CSF could be induced in other types 
of cells in the intestine, such as Paneth cells [49]. Thus, 
STAT5-mediated GM-CSF production in T cells may not 
be mandatory for colitis.
In summary, we found that a distinct subset of T help-
er cells (TH-GM), which is regulated by IL-7-STAT5 
signaling axis and predominantly produces GM-CSF and 
IL-3, is critical for autoimmune neuroinflammation.
Materials and Methods
Mice
Stat5f/f mice were provided by L Hennighausen (National Institute 
of Diabetes and Digestive and Kidney Diseases) [27]. Stat3f/f mice 
were generated as described [50]. Cd4-Cre transgenic mice were 
purchased from Taconic Farms. Rag2−/− mice were obtained from 
Jean-Pierre Abastado (Singapore Immunology Network). All mice 
are on a C57BL/6 genetic background and housed under specif-
ic-pathogen-free conditions at the National University of Singa-
pore. All experiments were performed with 6-8-week-old mice and 
approved by the Institutional Animal Care and Use Committee of 
NUS.
In vitro T-cell differentiation
CD4+ T cells were obtained from spleens and lymph nodes by 
positive selection and magnetic separation (Miltenyi Biotec), fol-
lowed by purification of naïve CD4+ T cell population (CD4+CD25−
CD62LhiCD44lo) sorted with FACS Aria. Naïve CD4+ T cells were 
stimulated with plate-bound anti-CD3 (3 µg/ml; BD Pharmingen) 
and anti-CD28 (1 µg/ml; BD Pharmingen) in the presence of 
different combinations of neutralizing antibodies and cytokines 
for 3-4 days: for neutral conditions, no addition of any cytokine 
or neutralizing antibody; for TH1 conditions, IL-12 (10 ng/ml), 
and anti-IL-4 (10 µg/ml, BD Pharmingen); for TH17 conditions, 
hTGF-β (3 ng/ml), IL-6 (20 ng/ml), anti-IFN-γ (10 µg/ml, eBiosci-
ence), and anti-IL-4 (10 µg/ml); for an alternative TH17 conditions, 
IL-6 (20 ng/ml), IL-23 (10 ng/ml), IL-1β (10 ng/ml), anti-IFN-γ (10 
µg/ml), and anti-IL-4 (10 µg/ml). For GM-CSF-producing cell dif-
ferentiation, naïve CD4+ T cells were stimulated with plate-bound 
anti-CD3 (3 µg/ml) and soluble anti-CD28 (1 µg/ml) with the ad-
dition of IL-7 (2 ng/ml) and/or anti-IFN-γ (10 µg/ml) as indicated. 
All cytokines were obtained from R&D Systems. All cells were 
cultured in RPMI 1640 supplemented with 10% FBS, 100 units/
ml penicillin, 0.1 mg/ml streptomycin, 1 mM sodium pyruvate, 0.1 
mM nonessential amino acid and 5 µM beta-mercaptoethanol. Af-
ter polarization for 3-4 days, cells were washed and restimulated 
with phorbol 12-myristate 13-acetate (PMA) and ionomycin in 
presence of Golgiplug for 4-5 h, followed by fixation and intracel-
lular staining with a Cytofix/Cytoperm kit from BD Pharmingen. 
Foxp3 staining was done with a kit from eBioscience. Cells were 
acquired on the LSR II (BD Biosciences) and analyzed with Flow-
Jo software (Tree Star).
EAE induction
EAE induction procedures were modified from a previous re-
port [51]. For active EAE induction, mice were immunized in two 
sites on the hind flanks with 300 µg MOG35-55 in 100 µl CFA con-
taining 5 mg/ml heat-killed M. tuberculosis strain H37Ra (Difco) 
on day 0 and day 7. Pertussis toxin (List Bio Lab) was adminis-
trated intraperitoneally at the dosage of 500 ng per mouse on day 
1 and day 8. For single MOG35-55/CFA immunization, the similar 
procedure was performed on day 0 and day 1 only. In an alterna-
tive active EAE induction, LPS (600 µg/ml in IFA, O111:B4 from 
Sigma) was used as adjuvant. For active EAE induction in Rag2−/− 
mice, CD4+ T cells derived from Stat5f/f or Cd4-Cre; Stat5f/f mice 
were transferred, followed by MOG35-55/CFA immunization as 
described above. Clinical symptoms were scored as follows: 0, no 
clinical sign; 1, loss of tail tone; 2, wobbly gait; 3, hind limb paral-
ysis; 4, hind and fore limb paralysis; 5, death. IL-7Rα neutralizing 
antibody (SB/14, BD Pharmingen) and isotype control was admin-
istrated intraperitoneally at 200 µg per mouse every other day. For 
analysis of CNS-infiltrating cells, both spinal cord and brain were 
collected and minced from perfused mice, and mononuclear cells 
were isolated by gradient centrifuge with Percoll (GE Healthcare).
For passive EAE induction with Stat5+/+ or Stat5−/− CD4+ T 
cells, splenocytes and LNs were harvested 10-14 days post-im-
munization and passed through a 70 µm cell strainer (BD Falcon). 
Cells were cultured in vitro for 3 days with MOG35-55 (20 µg/ml) 
in the presence of IL-23 (5 ng/ml) and IL-1β (2 ng/ml). After 
harvesting, CD4+ T cells were purified by positive selection to a 
purity > 90%. CD4+ T cells (2 × 106 in sterile PBS) were injected 
intraperitoneally into Rag2−/− mice, followed by Pertussis toxin 
administration on the following day. Mice were observed daily 
for the signs of EAE as described above. For EAE induction by 
transferring various TH subsets, similar procedures were performed 
as described above. Different subsets skewing conditions were as 
follows: Non-skewed, MOG35-55 only; TH1: MOG35-55 plus IL-12 
(10 ng/ml) and anti-IL-4 (5 µg/ml); TH17: MOG35-55 plus TGF-β 
(3 ng/ml), IL-6 (10 ng/ml), anti-IFN-γ (5 µg/ml) and anti-IL-4 (5 
µg/ml); GM-CSF-producing TH: MOG35-55 plus IL-7 (5ng/ml), and 
anti-IFN-γ (5 μg/ml). 6 × 105 CD4+ T cells were transferred per 
recipient mouse.
T-cell transfer model of colitis
CD4+ T cells were isolated from spleens and lymph nodes of 
WT, Cd4-Cre; Stat3f/f and Cd4-Cre; Stat5f/f mice by positive se-
lection and magnetic separation (Miltenyi Biotech). Naïve CD4+ 
T (CD4+CD25−CD45RBhi) cells were sorted with BD FACS Aria 
(purify > 98%). Rag2−/− mice were reconstituted with 4 × 105 
naïve CD4+ T cells via intraperitoneal injection. Intestine inflam-
mation was monitored up to 8 weeks. Cell suspensions were pre-
pared from spleen, MLNs, and colon lamina propria by methods 
modified from previous report [52].
Histological analysis
For paraffin-embedded tissues, spinal cords, or colons were 
fixed in 4% PFA. Sections (5 µm) were stained with hematoxylin 
and eosin (H&E) to assess immune cell infiltration and inflamma-
tion. For frozen tissues, spinal cords were embedded in OCT (Tis-
sue-Tek) and snap frozen on dry ice. Sections (10 μm) were fixed 
in ice-cold acetone and stained with primary anti-CD4 (Biolegend) 
and anti-CD11b (eBioscience), followed by incubation with fluo-
rescence-conjugated secondary antibodies (Invitrogen).
Real-time PCR
Total RNA was extracted from cells with RNeasy kit (Qiagen) 
according to the manufacturer’s instruction. Complementary DNA 
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(cDNA) was synthesized with Superscript reverse transcriptase 
(Invitrogen). Gene expressions were measured by 7500 real-time 
PCR system (Applied Biosystems) with SYBR qPCR kit (KAPA). 
Actinb, Gapdh, or Rn18S was used as internal control. The primer 
sequences are available upon request.
Microarray assay
For microarray analysis, RNA from naïve T cells, TH1, TH17 
and GM-CSF-producing TH cells was purified with RNeasy kit 
(Qiagen). Hybridization targets were amplified and labeled using 
Applause WT-Amp ST System according to the manufacturer’s 
protocol (NuGEN). Labeled cDNA was hybridized to Affymetrix 
GeneChip Mouse Gene 1.0 ST according to the manufacturer’s 
instructions. All microarray raw data (CEL files) were analyzed 
together using the Robust Multichip Average method to obtain the 
gene expression intensities. Normalization was then performed 
across all samples based on the cross correlation method [53]. 
Normalized data were further log2-tranformed and were used for 
identification of differentially expressed or TH-cell specific genes. 
The cutoff fold change threshold of 1.5 was used for differential 
expression.
ELISA
GM-CSF level was assayed by Ready-SET-Go ELISA kit 
(eBioscience) according to the manufactures’ instructions.
Chromatin immunoprecipitation assays
CD4+ T cells isolated from Stat5f/f or Cd4-Cre; Stat5f/f mice 
were activated with plate-bound anti-CD3 and anti-CD28 for 3 
days. Cells were stimulated with IL-7 (20 ng/ml) or IL-2 (25 ng/
ml) for 45 min. Crosslink was performed by addition of formalde-
hyde at final concentration of 1% for 10 min followed by quench-
ing with glycine. Cell lysates were fragmented by sonication and 
precleared with protein G Dynabeads, and subsequently precipi-
tated with anti-STAT5 antibody (Santa Cruz) or normal rabbit IgG 
(Santa Cruz) overnight at 4 °C. After washing and elution, cross-
link reversal was done by incubating at 65 °C for 8 h. The eluted 
DNA was purified and analyzed by RT-PCR with primers specific 
to Csf2 promoter as described previously [54].
Statistics
Statistical significance was determined by Student’s t-test using 
GraphPad Prism 6.01. P < 0.05 was considered significant. The 
P values of clinical scores were determined by one-way multi-
ple-range analysis of variance (ANOVA) for multiple compari-
sons. Unless otherwise specified, data were presented as mean ± 
SEM.
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